Journal of Clinical Oncology
Articles in this Issue
Moving Beyond Imaging in metastatic castration-resistant prostate cancer: Liquid biopsy cfNA profiling of <i>PTEN-FANCD2-POLQ</i> as molecular signatures of response to 177Lu-PSMA-617.
e17050 Background: 177Lu-PSMA-617 radioligand therapy (RLT) has demonstrated efficacy in metastatic castration-resistant p...
Four cycles of tislelizumab plus GP regimen as neoadjuvant therapy for high-risk (T4/N3) locally advanced nasopharyngeal carcinoma.
6089 Background: The efficacy of standard chemoradiotherapy for locally advanced nasopharyngeal carcinoma (LANPC) is still...
Neoadjuvant mitomycin C plus carboplatin followed by paclitaxel vs. standard doxorubicin–cyclophosphamide followed by paclitaxel–carboplatin in BRCA1/2-associated breast cancer.
620 Background: Triple-negative breast cancer (TNBC) associated with BRCA1/2 mutations is an aggressive disease subtype ch...
Pilocytic astrocytoma: An NCDB analysis of contemporary clinical and socioeconomic patterns.
e14082 Background: Pilocytic astrocytoma (PA) is a rare, low grade glioma, most commonly found in the cerebellum of pediat...
Influence of pirfenidone on checkpoint inhibitor pneumonitis and antitumor efficacy in NSCLC: A multicenter study and mechanistic exploration.
2609 Background: Checkpoint inhibitor pneumonitis (CIP) is a major fatal immune-related adverse events (irAEs) in immune c...
Prediction of survival outcome in clinical stage II-III non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy: Role of ypN status vs PCR.
8056 Background: After FDA approval in 2022, neoadjuvant chemoimmunotherapy has become the standard of care for patients w...
Resection and intracranial implant of (Z)- <i>n</i> -butylidenephthalide wafer followed by temozolomide as treatment for recurrent glioblastoma: A randomized phase IIb/III trial.
TPS2097 Background: Glioblastoma, an isocitrate dehydrogenase (IDH)–wildtype diffuse glioma, remains highly lethal despite...
Age as a surrogate: Mortality and vascular risk in gastrointestinal stromal tumor after frailty and comorbidity adjustment.
e23516 Background: Older adults with gastrointestinal stromal tumor (GIST) have worse survival than younger patients, typi...
Adjuvant immune checkpoint inhibitors combined with chemotherapy and lenvatinib for biliary tract cancer after curative resection: A single-center retrospective study.
e16269 Background: Surgery is the cornerstone of curative treatment for biliary tract cancer (BTC), yet only about 30% of...
EA3231: A randomized phase III study of BRAF-targeted therapy vs cabozantinib in RAI-refractory differentiated thyroid cancer with <i>BRAF</i> V600Em.
TPS6140 Background: About half of patients with RAIR advanced differentiated thyroid cancer (DTC) harbor a mutation in BRA...
Cardiovascular-related adverse events (CVD-AEs) and echocardiographic (Echo) changes with immunotherapy (IT): A real-world experience.
11185 Background: Immune-checkpoint inhibitors (ICI) are standard of care for many solid tumors but are linked to cardiova...
Evaluation of patient-reported gynecomastia following neoadjuvant androgen deprivation therapy and stereotactic body radiotherapy for localized prostate cancer.
e17125 Background: Androgen deprivation therapy (ADT) is commonly combined with stereotactic body radiotherapy (SBRT) for...
Equal Hope's Medicaid breast cancer coordination of care improvement initiative.
e13518 Background: In 2022, there were 11,000 breast cancer diagnoses and 1,600 deaths due to breast cancer in Illinois. C...
Circulating tumor DNA dynamics following molecularly targeted therapy for non–small cell lung cancer.
8652 Background: Biomarkers to guide treatment escalation following suboptimal response to molecular targeted therapy are...
The differentiated SIRPα–IgG4 Fc fusion protein HCB101 in monotherapy and combination therapy.
2655 Background: The CD47–SIRPα axis is a central innate immune checkpoint that enables tumor immune evasion. No prior CD4...
Evaluating the role of informal caregivers in metastatic cancer patients treated with oral anticancer therapy: A prospective observational study.
11117 Background: The increasing use of oral anticancer agents (OAAs) in metastatic cancer has shifted treatment managemen...
Retrospective evaluation of an AI-based fusion prioritization agent for oncogenicity assessment in clinical sequencing.
e18558 Background: Categorizing gene fusions as drivers or passengers is a data-intensive challenge requiring manual inter...
Outcomes of de novo del(17p) in multiple myeloma.
e19558 Background: Del(17p) (de novo) occurring in up to 10% of newly diagnosed myeloma patients is an independent risk fa...
Impact of shallow whole genome sequencing on diagnostic yield and prognostic precision in myelodysplastic syndromes.
6567 Background: Accurate cytogenetic characterization is critical for risk stratification in myelodysplastic syndromes (M...
Heterogeneity of interim PET partial metabolic response in DLBCL: Risk stratification using ΔSUVmax.
e19052 Background: Interim 18 F-FDG PET/CT (iPET) is widely used for response asse...
Radiotherapy followed by CAPOX plus tislelizumab in microsatellite-stable rectal cancer with synchronous resectable metastases: Updated results of the MIRACLE-1 study.
e15555 Background: Microsatellite-stable (MSS) tumors comprise ~95% of metastatic colorectal cancer cases and show low res...
Blood-derived small extracellular vesicle-based liquid biopsy for repeatable genomic and transcriptomic monitoring in adult-type diffuse glioma.
e14081 Background: Adult-type diffuse glioma is an aggressive primary brain tumor characterized by profound spatial and te...
Real-world evidence on changes in uptake, sepsis, and costs with dual immunotherapy for first-line NSCLC.
e20701 Background: The addition of immunotherapy to platinum-based chemotherapy regimens has transformed first-line treatm...
Predictors of low- and high-grade ICANS after CAR-T: A nationwide analysis.
7036 Background: Immune effector cell-associated neurotoxicity syndrome (ICANS) is a leading cause of morbidity following...
Impact of variant topography of <i>NPM1</i> mutations in acute myeloid leukemia.
6536 Background: NPM1 is a frequent driver mutation in AML and conveys favorable prognosis in the abse...